Common errors in multidrug-resistant tuberculosis management

Expert Review of Respiratory Medicine

Volumn 8, Issue 1, 2014, Pages 15-23

  Monedero, Ignacio ^a,b   Caminero, Jose A ^a,c  

^a INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

^b HOSPITAL CLÍNIC   (Spain)

^c HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

Author keywords

clinical management; errors; extensively drug resistance; multidrug resistance; tuberculosis; XDR

Indexed keywords

AMIKACIN; CAPREOMYCIN; CIPROFLOXACIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; OFLOXACIN; QUINOLONE DERIVATIVE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

DEVELOPING COUNTRY; DIAGNOSTIC ERROR; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HUMAN; MEDICAL ERROR; MEDICATION COMPLIANCE; MONOTHERAPY; MULTIDRUG RESISTANT TUBERCULOSIS; REVIEW; THERAPEUTIC ERROR; TREATMENT DURATION;

ADMINISTRATION, ORAL; ANTITUBERCULAR AGENTS; DEVELOPING COUNTRIES; DIAGNOSTIC ERRORS; DISEASE MANAGEMENT; DRUG DELIVERY SYSTEMS; HUMANS; INJECTIONS; ISONIAZID; MEDICATION ERRORS; RIFAMPIN; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84893088529     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/17476348.2014.856758     Document Type: Review

References (48)

1. WHO. Global Tuberculosis Report 2012. WHO/HTM/TB/2012.6. WHO, Geneva, Switzerland (2012).
2. Raviglione MC, Smith IM. XDR tuberculosis-implications for global public health. N. Engl. J. Med. 356(7), 656-659 (2007).
3. Royce S, Falzon D, Van Weezenbeek C. et al.: Multidrug resistance in new tuberculosis patients: Burden and implications. Int. J. Tuberc. Lung Dis. 17(4), 511-513 (2013).
4. WHO. Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. An Emergency Update. WHO/HTM/TB/2008.402. WHO, Geneva, Switzerland (2008).
5. Keshavjee S, Farmer PE. Tuberculosis, drug resistance, and the history of modern medicine. N. Engl. J. Med. 367(10), 931-936 (2012).
6. Monedero I, Caminero JA. MDR-/XDRTB management: What it was, current standards and what is ahead. Expert Rev. Respir. Med. 3(2), 133-145 (2009).
7. Caminero J. Treatment of multidrug-resistant tuberculosis: Evidence and controversies. Int. J. Tuberc. Lung Dis. 10(8), 829-837 (2006).
8. WHO. Multidrug and Extensively Drug-Resistant TB (M/XDR-TB): 2010 Global Report on Surveillance and Response. WHO/HTM/TB/2010.3. WHO Press, Geneva, Switzerland (2010).
9. Orenstein EW, Basu S, Shah NS. et al.: Treatment outcomes among patients with multidrug-resistant tuberculosis: Systematic review and meta-Analysis. Lancet Infect. Dis. 9(3), 153-161 (2009).
10. Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment outcomes of multidrug-resistant tuberculosis: A systematic review and meta-Analysis. PLoS ONE 4(9), e6914 (2009).
11. Jacobson KR, Tierney DB, Jeon CY, Mitnick CD, Murray MB. Treatment outcomes among patients with extensively drug-resistant tuberculosis: Systematic review and meta-Analysis. Clin. Infect. Dis. 51(1), 6-14 (2010).
12. Seita A. The critical challenge in tuberculosis programmes: Are we thinking critically? Int. J. Tuberc. Lung Dis. 13(12), 1444-1446 (2009).
13. Iuatld. Management of Tuberculosis. A Guide to the Essentials of Good Practice. Internacional Union Against Tuberculosis and Lung Diseases (The Union), Paris, France (2010).
14. Monedero I, Caminero JA. Management of multidrug-resistant tuberculosis: An update. Ther. Adv. Respir. Dis. 4(2), 117-127 (2010).
15. Caminero J. Multidrug-resistant tuberculosis: Epidemiology, risk factors and case finding. Int. J. Tuberc. Lung Dis. 14(4), 382-390 (2010).
16. Yagui M, Perales MT, Asencios L. et al.: Timely diagnosis of MDR-TB under program conditions: Is rapid drug susceptibility testing sufficient? Int. J. Tuberc. Lung Dis. 10(8), 838-843 (2006).
17. WHO. Treatment of Tuberculosis: Guidelines (4th Edition). WHO/HTM/TB/2009.420. Geneva, Switzerland (2009).
18. Menzies D, Benedetti A, Paydar A. et al.: Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: A systematic review and meta-Analysis. PLoS Med. 6(9), e1000146 (2009).
19. Caminero J. Management of multidrug-resistant tuberculosis and patients in retreatment. Eur. Respir. J. 25(5), 928-936 (2005).
20. Kim S. Drug-susceptibility testing in tuberculosis: Methods and reliability of results. Eur. Respir. J. 25(3), 564-569 (2005).
21. Canetti G. Present aspects of bacterial resistance in tuberculosis. Am. Rev. Respir. Dis. 92(5), 687-703 (1965).
22. Kim SJ, Espinal MA, Abe C. et al.: Is second-line anti-Tuberculosis drug susceptibility testing reliablé Int. J. Tuberc. Lung Dis. 8(9), 1157-1158 (2004).
23. Van Deun A, Martin A, Palomino JC. Diagnosis of drug-resistant tuberculosis: Reliability and rapidity of detection. Int. J. Tuberc. Lung Dis. 14(2), 131-140 (2010).
24. Richter E, Rüsch-Gerdes S, Hillemann D. Drug-susceptibility testing in TB: Current status and future prospects. Expert Rev. Resp. Med. 3(5), 497-510 (2009).
25. WHO. Policy Guidelines on Drug-Susceptibility Testing (DST) of Second-Line Antituberculosis Drugs. WHO/ HTM/2008.392, WHO, Geneva, Switzerland (2008).
26. Iseman M. Treatment of multidrug-resistant tuberculosis. N. Engl. J. Med. 329(11), 784-791 (1993).
27. Mitchison D. Bactericidal mechanisms in short-course chemotherapy. Bull. Int. Union Tuberc. 53, 254-259 (1978).
28. Caminero JA, Van Deun A, Fujiwara PI. et al.: Guideline for the Clinical and Operational Management of Drug Resistant Tuberculosis Internacional Union Against Tuberculosis and Lung Diseases, Paris, France (2013).
29. WHO. Rapid Implementation of the Xpert MTB/RIF Diagnostic Test Technical and Operational 'How-To' Practical Considerations. WHO/HTM/TB/2011.2. WHO, Geneva, Switzerland (2011).
30. Caminero Luna JA. A Tuberculosis Guide for Specialist Physicians. International Union Against Tuberculosis and lung Diseases, Paris, France. (2004).
31. Caminero J. Likelihood of generating MDR-TB and XDR-TB under adequate National Tuberculosis Control Programme implementation. Int. J. Tuberc. Lung Dis. 12(8), 869-877 (2008).
32. Ahuja SD, Ashkin D, Avendano M. et al.: Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: An individual patient data meta-Analysis of 9, 153 patients. PLoS Med. 9(8), e1001300 (2012).
33. Falzon D, Gandhi N, Migliori GB. et al.: Resistance to fluoroquinolones and second-line injectable drugs: Impact on multidrug-resistant TB outcomes. Eur. Respir. J. 42(1), 156-168 (2012).
34. Bate R, Jensen P, Hess K, Mooney L, Milligan J. Substandard and falsified anti-Tuberculosis drugs: A preliminary field analysis. Int. J. Tuberc. Lung Dis. 17(3), 308-311 (2013).
35. Rusen ID, Harries AD, Heldal E, Mace C. Drug supply shortages in 2010: The inexcusable failure of global tuberculosis control. Int. J. Tuberc. Lung Dis. 14(3), 253-254 (2010).
36. Van Deun A, Maug AK, Salim MA. et al.: Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am. J. Respir. Crit. Care Med. 182(5), 684-692 (2010).
37. PIH. Guide for the Treatment and MANAGEMENT of MDR-TB. Partners In Health, Boston, MA, USA (2003).
38. Coyne KM, Pozniak AL, Lamorde M, Boffito M. Pharmacology of second-line antituberculosis drugs and potential for interactions with antiretroviral agents. AIDS 23(4), 437-446 (2009).
39. Peloquin CA, Berning SE, Nitta AT. et al.: Aminoglycoside toxicity: Daily versus thrice-weekly dosing for treatment of mycobacterial diseases. Clin. Infect. Dis. 38(11), 1538-1544 (2004).
40. De Jager P, Van Altena R. Hearing loss and nephrotoxicity in long-Term aminoglycoside treatment in patients with tuberculosis. Int. J. Tuberc. Lung Dis. 6(7), 622-627 (2002).
41. Rodriguez M, Monedero I, Caminero JA. et al.: Successful management of multidrug-resistant tuberculosis under programme conditions in the Dominican Republic. Int. J. Tuberc. Lung Dis. 17(4), 520-525 (2013).
42. IUATLD. Management of Tuberculosis. A Guide to Essentials of Good Practice. International Union Against Tuberculosis and Lung Disease, Paris, France (2010).
43. WHO. Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis -2011 Update. WHO/HTM/TB/2011.6. WHO, Geneva, Switzerland (2011).
44. Sterling TR, Lehmann HP, Frieden TR. Impact of DOTS compared with DOTS-plus on multidrug resistant tuberculosis and tuberculosis deaths: Decision analysis. BMJ 326(7389), 574 (2003).
45. Toczek A, Cox H, Du Cros P, Cooke G, Ford N. Strategies for reducing treatment default in drug-resistant tuberculosis: Systematic review and meta-Analysis. Int. J. Tuberc. Lung Dis. 17(3), 299-307 (2012).
46. Horsburgh CR, Haxaire-Theeuwes M, Lienhardt C. et al.: Compassionate use of and expanded access to new drugs for drug-resistant tuberculosis [Review article]. Int. J. Tuberc. Lung Dis. 17(2), 146-152 (2013).
47. Mitchison D. Pharmacokinetic/ pharmacodynamic parameters and the choice of high-dosage rifamycins. Int. J. Tuberc. Lung Dis. 16(9), 1186-1189 (2012).
48. Dooley KE, Mitnick CD, Ann Degroote M. et al.: Old drugs, new purpose: Retooling existing drugs for optimized treatment of resistant tuberculosis. Clin. Infect. Dis. 55(4), 572-581 (2012).